BLDR vs CNH

The company exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet fundamentals. However, despite this strength, the business is facing significant near-term headwinds, evidenced by sharp year-over-year declines in revenue (-6.9%) and earnings (-54.9%), which are weighing on performance. Valuation metrics suggest the stock is trading at a premium to both Graham’s defensive value ($67.26) and growth-based intrinsic value ($36.05), though below the sector’s elevated average P/E. Analysts maintain a 'buy' recommendation with a $131.00 target, implying upside potential if macro or operational conditions improve.

CNH presents a conflicting profile: a strong Piotroski F-Score of 7/9 indicates solid operational health, yet the stock is plagued by a severe earnings collapse (-50.10% YoY) and a completely bearish technical trend (0/100). While the PEG ratio of 0.60 suggests significant undervaluation relative to growth potential, the current price of $10.25 trades at a premium to the Graham Number ($7.58) and the growth-based intrinsic value ($2.87). The disconnect between bullish analyst targets ($13.88) and the consistent multi-year price decline suggests a value trap risk despite strong short-term liquidity.